NCT03951831View on ClinicalTrials.gov

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2028

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

REGN2810

Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.

DRUG

Degarelix

Degarelix is administered subcutaneously (SC) at a dose of 240mg once.

DRUG

Leuprolide Acetate

Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.

DRUG

Docetaxel

Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Mark Stein

OTHER

NCT03951831 - REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter